TENX
TENAX THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.81
−1.63%Oct 30, 2026, 13:00 UTC
Law Offices of Howard G. Smith announced that it is investigating whether Tenax Therapeutics violated federal securities laws.
Source:Oct 30, 2026, 00:40 UTC
A class action lawsuit was filed against Tenax Therapeutics on behalf of investors who acquired its securities between November 13, 2023 and August 7, 2026.
Oct 29, 2026, 19:46 UTC
Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims involving TENAX THERAPEUTICS, INC.
Source:Aug 31, 2026, 11:07 UTC
Tenax Therapeutics shares rose 3.8% in premarket trading after presenting additional data from its Phase 3 LEVEL trial of TNX-103 at the European Society of Cardiology Congress in Munich.
Source:Aug 24, 2026, 23:46 UTC
ADAR1 Capital Management, a 10% owner and director of Tenax Therapeutics, acquired 1,025,867 common shares totaling approximately $1.81 million over several days from August 20 to August 24, 2026.
Source:Aug 10, 2026, 11:00 UTC
Tenax Therapeutics announced topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF, which did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo.
Jul 31, 2026, 00:00 UTC
Tenax Therapeutics reported a net loss of $17.8 million for Q2 2026, with diluted EPS of -$0.35, and held $118.0 million in cash and cash equivalents as of June 30, 2026.